Issue Price
₹1,500
Per Share
GMP
NIL
Grey Market
Est. Listing
₹1,500
Expected Price
Min. Application
₹30,000
2 lots × 10 shares
Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.Company StrengthsThe extensive product portfolio of complex injectables.Diversified B2B model with a targeted B2C model in India.Strong manufacturing capabilities.Robust financial track record.Experienced and qualified managerial team.
Gland Pharma Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
| Category | Shares Offered | % Issue | Amount (₹ Cr)* | Subscription |
|---|---|---|---|---|
| TOTAL | 43,196,968 | 100.00% | ₹6,479.55 Cr | — |
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 10 | ₹15,000 |
| Retail (Max) | 13 | 130 | ₹195,000 |
| sNII (Min) | 14 | 140 | ₹210,000 |
| bNII (Min) | 68 | 680 | ₹1,020,000 |
| Particulars | 30-June-20 | 31-Mar-20 | 31-Mar-19 |
|---|---|---|---|
| Revenue from Operations | 916.29 | 2772.41 | 2129.77 |
| EBITDA | N/A | N/A | N/A |
| Profit After Tax (PAT) | 313.59 | 772.86 | 451.86 |
| Net Worth | N/A | N/A | N/A |
| Total Assets | 4691.27 | 4086.04 | 3523.55 |
| Reserves & Surplus | N/A | N/A | N/A |
| Total Borrowings | N/A | N/A | N/A |